RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase that will support its upcoming U.S. Food and Drug Administration (“FDA”) submission. These results represent a significant advancement from the initial data obt ...

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more standard-of-care ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES TORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Partners Value Split Corp. (the “Company”) announced today the completion of its previously announced offering of Class AA Preferred Shares, Series 16 (the “Series 16 Preferred Shares”). A total of 4,000,000 Series 16 Preferred Shares were issued at an offering price of US$25.00 per Series 16 Preferred Share, raising gross proceeds of US$100,000,000. The issuance included 1,000,00 ...

LOWELL, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor products, today announced the availability of a new chipset to overcome the distance limitations of traditional PCI Express (PCIe) and Compute Express Link (CXL) connectivity by enabling high speed, low latency communication over optical fiber. Designed to maintain signal integrity and reduce latency, the chipset consists of the MATA-38794 transimpedance amplifier (TIA) and the MA ...

Singapore, Sept. 11, 2025 (GLOBE NEWSWIRE) -- YY Group Holding Limited (Nasdaq: YYGH) (“YY Group” or the “Company”) today announced the amendment of its previously announced registered direct offering. The Company and the investors have entered into an amended and restated securities purchase agreement, pursuant to which the Company will offer 9,523,812 Class A Ordinary shares and warrants to purchase up to 14,285,718 Class A Ordinary Shares at a purchase price of $0.42 per share and accompanying warrants. ...

XHLD Riding the $1 Trillion Wave of Scalable Event Tech InnovationDENVER, Sept. 11, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that TEN Holdings (NASDAQ: XHLD), a provider of event planning, production, and broadcasting services through its operating subsidiary Ten Events, is demonstrating robust execution and progress on its Ten Events Pro (“Ten Pro”) SaaS platform. The pivot to a Saa ...

产品发布 - 公司推出首款商业与工业(C&I)储能解决方案 250kW/430kWh电池储能系统(BESS) [1] - 新产品具备250kW功率容量和430kWh可用能量 采用模块化可扩展设计 [7] - 系统集成需求管理和分时优化控制 兼容太阳能、发电机和电网并网配置 [7] 产品特性 - 专为商业地产、工业场地和微电网应用设计 提供能源独立性和备用电源弹性 [2] - 采用与住宅系统相同的安全优先方法和安装中心设计理念 [2] - 适用于电网服务和备用电源应用场景 [7] 市场战略 - 进军C&I市场是公司自然演进 致力于满足从住宅到大型商业的全谱系储能需求 [2] - 通过授权分销商和直接销售面向大型项目 2025年第四季度开始安装 [2] - 在RE+ 2025展会接受商业项目咨询 展位号V12313 [1][2] 公司背景 - 公司是能源存储解决方案领域的领先创新者 专注于清洁能源未来发展 [4] - 产品旨在满足住宅和商业应用对高效能源管理日益增长的需求 [4] - 通过尖端技术和战略合作伙伴关系推动可再生能源进步 [4]

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 1,500,000 of the Company’s ordinary shares (or ordinary share equivalents), series A warrants to purchase up to 1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary shares at a comb ...

核心观点 - 前Tanox公司首席执行官Nancy T Chang博士加入Immix Biopharma董事会 同时作为Goose Capital创始成员进行投资[1] - Chang博士领导团队开发了多款FDA批准药物 包括XOLAIR®、TROGARZO®和EBGLYSS® 累计销售额超过50亿美元[2] - Immix Biopharma为临床阶段生物制药公司 专注于开发AL淀粉样变性及其他严重疾病的细胞疗法[3] 公司管理层变动 - Nancy T Chang加入Immix Biopharma董事会 其曾担任Tanox公司CEO[1] - Chang博士作为Goose Capital创始成员对公司进行投资[1] 行业经验与成就 - Chang博士团队发明并开发了XOLAIR®（奥马珠单抗）用于治疗严重哮喘[2] - 开发TROGARZO®（伊巴珠单抗）用于HIV治疗[2] - 开发EBGLYSS®（来金珠单抗）用于皮炎治疗[2] - 三款药物累计销售额超过50亿美元[2] - Tanox公司被Genentech/Roche以9.19亿美元收购[2] - EBGLYSS®由礼来公司商业化[2] 公司产品管线 - 主要候选药物为NXC-201 一种空间优化的BCMA靶向CAR-T细胞疗法[3] - NXC-201采用"数字过滤器"技术 可过滤非特异性激活[3] - 正在美国进行多中心研究NEXICART-2（NCT06097832）针对复发/难治性AL淀粉样变性[3] - NEXICART-2研究采用注册性设计 在ASCO 2025公布的中期结果中达到主要终点[3] - NXC-201获得美国FDA授予再生医学先进疗法（RMAT）资格[3] - 获得FDA和EMA授予孤儿药资格（ODD）[3] 公司背景 - Immix Biopharma为纳斯达克上市公司 代码IMMX[3] - 专注于开发AL淀粉样变性及其他严重疾病的细胞疗法[3] - 公司处于临床阶段[3]

SHANGHAI, China, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Hesai Group (NASDAQ: HSAI) (“Hesai” or the “Company”), the global leader in three-dimensional light detection and ranging (lidar) solutions, today announced the pricing of its global offering (the “Global Offering”) of 19,550,000 Class B ordinary shares of the Company (the “Offer Shares”), which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering”). The final offering price for ...